ID   ACT-1 [Human thyroid carcinoma]
AC   CVCL_6291
SY   ACT1
DR   BTO; BTO_0004858
DR   cancercelllines; CVCL_6291
DR   CCRID; 3101HUMSCSP541
DR   Cosmic; 1152115
DR   Cosmic; 1239968
DR   Cosmic; 2054109
DR   Wikidata; Q54608560
RX   PubMed=12495476;
RX   PubMed=18713817;
RX   PubMed=23833040;
RX   PubMed=26137260;
RX   PubMed=26680454;
RX   PubMed=30737244;
CC   From: Ohata, Seiji; Tokushima University; Tokushima; Japan.
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys242Ser (c.725G>C); ClinVar=VCV000647334; Zygosity=Homozygous (PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=18713817; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,12
ST   D16S539: 9,11
ST   D18S51: 15,16
ST   D21S11: 30,31
ST   D3S1358: 16
ST   D5S818: 11,13
ST   D7S820: 10,11
ST   D8S1179: 11,14
ST   FGA: 23,24
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 23
//
RX   PubMed=12495476; DOI=10.1111/j.1349-7006.2002.tb01245.x; PMCID=PMC5926938;
RA   Chung S.-H., Onoda N., Ishikawa T., Ogisawa K., Takenaka C., Yano Y.,
RA   Hato F., Hirakawa K.;
RT   "Peroxisome proliferator-activated receptor gamma activation induces
RT   cell cycle arrest via the p53-independent pathway in human anaplastic
RT   thyroid cancer cells.";
RL   Jpn. J. Cancer Res. 93:1358-1365(2002).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=26137260; DOI=10.3892/mco.2015.496; PMCID=PMC4471583;
RA   Onoda N., Nakamura M., Aomatsu N., Noda S., Kashiwagi S., Kurata K.,
RA   Uchino S., Hirakawa K.;
RT   "Significant cytostatic effect of everolimus on a gefitinib-resistant
RT   anaplastic thyroid cancer cell line harboring PI3KCA gene mutation.";
RL   Mol. Clin. Oncol. 3:522-526(2015).
//
RX   PubMed=26680454; DOI=10.1186/s12885-015-1955-9; PMCID=PMC4683857;
RA   Kasaian K., Wiseman S.M., Walker B.A., Schein J.E., Zhao Y.-J.,
RA   Hirst M., Moore R.A., Mungall A.J., Marra M.A., Jones S.J.M.;
RT   "The genomic and transcriptomic landscape of anaplastic thyroid
RT   cancer: implications for therapy.";
RL   BMC Cancer 15:984.1-984.11(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//